The Quantellect read.As of Nov 19, 2026, 7 active firms cover Adaptive Biotechnologies Corp: 6 rate it Buy or better, 1 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $19.00 to $35.00, a moderate spread. The average target of $29.50 sits 4% above the current $28.43. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 5 to 6 over recent months. On the fundamentals, the Street sees revenue growth near 4% this year and 22% next, consensus EPS building from about $-0.10 next quarter toward $-0.03 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 active firms
Buy
Strong Buy00%
Buy686%
Neutral114%
Sell00%
Strong Sell00%
Based on 7 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$29.50
+3.8% upside
Average target across 7 active firms as of Nov 19, 2026 vs $28.43 current
Highest Target$35.00
Average Target$29.50
Lowest Target$19.00
Detailed analyst forecasts for ADPT
Showing 1–7 of 7 named analysts shown · 7 active firms in the rating projection
As of Nov 19, 2026, 6 of 7 active firms rate ADPT a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
ADPT EPS & revenue forecast
EPS · NEXT QUARTER
$-0.10
Range $-0.10 – $-0.10 · 2 analysts · -23% YoY
Next period, 2 analysts expect Adaptive Biotechnologies Corp to earn $-0.10 a share (range $-0.10 – $-0.10), versus $-0.13 a year earlier. Full-year consensus is $-0.37, growing to $-0.03 the year after.
REVENUE · NEXT QUARTER
$80.4M
Range $77.7M – $82.8M · 2 analysts · -25% YoY
Revenue is expected to reach $80.4M (range $77.7M – $82.8M), -25.0% year-over-year. Full-year consensus is $307.0M, rising to $373.3M next year.
Top analysts covering Adaptive Biotechnologies Corp
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ADPT.
#1
SJ
Sung Ji Nam
Scotiabank · Rank #186
Buy
$12.00-57.8% to target
Overall win rate
47%
+ Follow
#2
Mark Massaro
BTIG · Rank #220
Buy
$34.00+19.6% to target
Overall win rate
44%
+ Follow
#3
David Westenberg
Piper Sandler · Rank #314
Buy
$27.50-3.3% to target
Overall win rate
35%
+ Follow
#4
Subbu Nambi
Guggenheim
Buy
$32.00+12.6% to target
Coverage
—
+ Follow
#5
SS
Sebastian Sandler
JP Morgan
Buy
$27.00-5.0% to target
Coverage
—
+ Follow
ADPT stock forecast FAQ
What is ADPT's average 12-month price target?+
The 7 active firms with a live target average $29.50 for Adaptive Biotechnologies Corp over the next 12 months, ranging from a $35.00 high to a $19.00 low, as of Nov 19, 2026.
Is ADPT stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 7 active firms as of Nov 19, 2026, 6 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for ADPT?+
The Street-high target is $35.00 (Goldman Sachs), and the Street-low is $19.00 (JP Morgan). The average of all 7 active-firm targets is $29.50.
How many active Wall Street firms cover ADPT?+
7 active firms have a recognized rating on Adaptive Biotechnologies Corp as of Nov 19, 2026, and 7 active firms carry a live 12-month price target.
Who is the most accurate analyst covering ADPT?+
Among analysts who currently cover ADPT, Sung Ji Nam of Scotiabank has the strongest overall Quantellect track record (Rank #186). Their current call is Buy with a $12.00 target.
What is Adaptive Biotechnologies Corp's projected EPS for next quarter?+
The consensus estimate is $-0.10 per share (range $-0.10 – $-0.10) across 2 analysts. Full-year EPS is projected at $-0.37, rising to $-0.03 the following year.
How much revenue is Adaptive Biotechnologies Corp expected to report next quarter?+
Consensus revenue is $80.4M (range $77.7M – $82.8M). Full-year revenue is projected at $307.0M, growing to $373.3M next year.
Have analysts been upgrading or downgrading ADPT lately?+
As of Nov 19, 2026, 6 of 7 active firms rate ADPT a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ADPT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.